Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- March - May 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- 2,6-bis[[bis(2-hydroxyethyl)amino]methyl]-4-nonylphenol
- EC Number:
- 243-500-6
- EC Name:
- 2,6-bis[[bis(2-hydroxyethyl)amino]methyl]-4-nonylphenol
- Cas Number:
- 20073-51-2
- Molecular formula:
- C25H46N2O5
- IUPAC Name:
- 2,6-bis{[bis(2-hydroxyethyl)amino]methyl}-4-nonylphenol
- Test material form:
- liquid: viscous
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- RccHan: WIST. Female, Nulliparous and non pregnant. 8-9 weeks old
- Sex:
- female
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The route of vehicle and test item administration was oral through gavage and was selected after discussion with the sponsor.
- Vehicle:
- corn oil
- Duration of treatment / exposure:
- The duration of dosing was for 14 days. The first day of dose administration was designated as day 1 for each rat.
- Frequency of treatment:
- Dose formulation was administered once daily by oral gavage at approximately the same time each day using intubation cannula attached to a graduated syringe.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5 animals of each sex at each dose.
- Control animals:
- yes
- Positive control:
- No positive control
Examinations
- Observations and examinations performed and frequency:
- All rats were observed twice a day for visible clinical signs during treatment period.
- Sacrifice and pathology:
- All surviving rats were fasted overnight (with ad libitum supply of drinking water) prior to sacrifice. At terminal sacrifice and morbidity, rats were ehtanized by carbon dioxide asphyxiation and subjected to a full gross necropsy under the direct supervision of a veterinary pahtologist. Rats, which were found dead or sacrificed under moribund condition, were subjected to post-mortem examination. Rats were examined carefully for external abnoramlities. The thoracic and abdominal cavities were opened and a thorough examination of the argnas was carried out to detect any abnormalities.
- Other examinations:
- Food consumption was measured daily.
All organs were weighed from all surviving rats.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- All rats belonging to vehicle control group were found normal throughout the treatment period. The observed clinical signs were:
weakness, polyuria,piloerection, salivation, - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Mortality and morbidity
No morbidity and mortality was observed in rats from vehicle control and low dose groups.
Three mortalities were observed in high dose group. Two mortalities qwere observed in mid dose group.
Three male and four female rats were sacrificed under moribund condition in high dose group. Three male and five female rats were sacrificed udner moribund condition in mid dose group.
The rats sacrificed under moribund condition and mortality observed in mid and high dose groups were considered as treatment related as the mortality observed after showing severe clinical sign. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant decrease in mean body weight was observed in male and female rats of low dose group on treatment days 8, 11 and 14 as compared with that of the control group.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant reduction in mean food consumption in low dose group was observed in male rats during treatment days 8-11 and in female rats during treatment days 4-8 and 1-14 as compared with that of the control gorup. Similar reduciton in mean food consumption without statistical significance in low dose group was observed in male rats during treatment days 1-4, 4-8, 11-14, and 1-14. $Reduction i9n food consumption was considered as weffect of test item as concurrent decrease ind boyd weight and body weight change was observed.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- In male rats, statistically significant decrease in terminal body weight and absolute weight of thymus, prostate, and Levator ani plus bulbocavernosus muscles was observed in low dose group.
Statistically signifcant increase in relative weight of brain and testes and statistically significant decrease in relative weight of prostate was observed in low dose group as compared with that of the control group.
Increase in relative weight of brain and testes could be correlated with decreased terminal body weight. Whereas decreased in absolute weight of thymus, prostate and LABC and relative weight of rpostate could be consdiered as effect of test item.
In female rats, statistically signifcant decrease in terminal body weight and increase in absolute weight of spleen was observed in low dose group as compared with that of the control group. Statistically significant increase in relative weight of spleen and brain was observed in low dose group as compared with that of the control group.
Increase in relative weight of brain could be correlated with decreased terminal body weight, whereas increased in absolute and relative weight of spleen could be considered as effect of test item.
Decreased in terminal body weiht was considered as effect of test item as it could be correlated with decreasesed body weight adn food consumption. - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- External examination of found dead, moribundly sacrificed, and termianlly sacrificed rats of either sex belonging to all groups did not revaeal any abnormality.
Internal examination of found dead male rats revelaed gaseous distension of stomach (in 3 of 4 rats) gaseous distension of itnestine (1in 4 rats) and whitish foci - non glandular stomach (in 1 of 4 rats) whereas internal examination of found dead female rat revealed gaseous distension of stomach.
Internal examination of moribundly sacrificed male reats revealed gaseous distension of stomach (in 2 of 6 rats), whitish foci - non glandular stomach (in 6 of 6 rats), and reddish foci -non glandular stoamch (in 1 o f 6 rats) whereas internal examination of moribundly sacrifcie female rats revelaed gaseous distension of stomach (in 5 of 9 rats) and whitish foci -n on glandular sotamch (in 8 of 9 rats).
Internal examination of terminally sacrificed rats of either sex belonging to vehicle control and low dose groups did not reveal any abnormality.
Changes observed during internal examination of found dead and moribundly sacrificed rats were considered as effects of test item. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- External examination of found dead, moribundly sacrificed, and termianlly sacrificed rats of either sex belonging to all groups did not revaeal any abnormality.
Internal examination of found dead male rats revelaed gaseous distension of stomach (in 3 of 4 rats) gaseous distension of itnestine (1in 4 rats) and whitish foci - non glandular stomach (in 1 of 4 rats) whereas internal examination of found dead female rat revealed gaseous distension of stomach.
Internal examination of moribundly sacrificed male reats revealed gaseous distension of stomach (in 2 of 6 rats), whitish foci - non glandular stomach (in 6 of 6 rats), and reddish foci -non glandular stoamch (in 1 o f 6 rats) whereas internal examination of moribundly sacrifcie female rats revelaed gaseous distension of stomach (in 5 of 9 rats) and whitish foci -n on glandular sotamch (in 8 of 9 rats).
Internal examination of terminally sacrificed rats of either sex belonging to vehicle control and low dose groups did not reveal any abnormality.
Changes observed during internal examination of found dead and moribundly sacrificed rats were considered as effects of test item. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
Effect levels
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- ca. 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical signs
- food consumption and compound intake
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 250 mg/kg bw/day (nominal)
- System:
- other: lymphatic system
- Organ:
- thymus
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Based on the results of present study, under the condition and procedures followed, dose levels of 1000 and 500 mg /kg b.wt. produced severe toxictiy viz. treatment related mortality, morbidity, and adverse clinical signs whereas a dose level of 250 mg/kg b. wt. porduced mild toxicity viz. decreased body weight change (7.90% in males), food consumption and treatment related changes in absolute and relative organ weight. Hence, following dose levels are suggested for reproduction/developmental toxicity screening study (dose range finding study):
Option Low dose Mid dose High dose (mg/kg)
I 15 50 150
II 15 60 240
III 20 60 180 - Executive summary:
EXECUTIVE SUMMARY: The study was conducted to determine the adverse effects occurring as result of repeated daily administration of the POLIOL MB 600 in Wistar rat for a period of 14 consecutive days and to select the dose levels for further reproductive/developmental toxicity screening study.
Method:
Test Item
POLIOL MB 600
Test System
Wistar strain (RccHan:WIST)
Route of Administration
Oral through gavage
Dose Levels (mg/kg b. wt./day)
G1 (vehicle control): 0; G2 (low dose): 250; G3 (mid dose): 500; G4 (high dose): 1000
Duration of Treatment
14 days
N° of Rats
5 rats/sex/group
Frequency of Dose Formulation Preparation
Daily fresh preparation
All rats were observed twice a day for mortality, morbidity and visible clinical signs throughout the
treatment period. Body weight of all surviving rats was recorded on days 1, 4, 8, 11, 14 and 15. Foodconsumption was calculated during treatment period for all surviving rats. At terminal sacrifice, surviving
rats were sacrificed by carbon dioxide asphyxiation and subjected to gross pathological examination.Absolute organ weights for all surviving rats were recorded and relative organ weights were calculated for
the organs: liver, kidneys, adrenals, testes, epididymis, prostate, LABC, seminal vesicle with coagulatinggland, thymus, heart, brain, spleen, uterus with cervix, and ovaries.
Results:
POLIOL MB 600 at 250 mg/kg b. wt. /day
No mortality was observed.
Salivation was observed in all male and female rats from treatment day 8.
Treatment related decrease in body weight, body weight change, food consumption and
terminal body weight were observed in male and female rats.In male rats, statistically significant decrease in absolute weight of thymus, prostate, and LABC
and relative weight of prostate were observed. In female rats, statistically significant increasein absolute and relative weight of spleen was observed. These changes in organ weights
(absolute and relative) were considered as treatment related however adversity of effect couldnot be established due to limited end-points of this study.
External and internal examination of rats of either sex did not reveal any abnormality.
POLIOL MB 600 at 500 mg/kg b. wt. /day
Two mortalities (two male rats) were observed.
Three male and five female rats were sacrificed under moribund condition.
Treatment related clinical signs viz. weakness, salivation, piloerection (only in male rats) and polyuria were observed in all male and female rats.
Internal examination of found dead male rats revealed gaseous distension of stomach (in 1 of rats) and whitish foci – non-glandular stomach (in 1 of 2 rats).
Internal examination of moribundly sacrifice male rats revealed gaseous distension of stomach (in 1 of 3 rats) and whitish foci – non-glandular stomach (in 3 of 3 rats).
Internal examination of moribundly sacrifice female rats revealed gaseous distension of stomach (in 2 of 5 rats) and whitish foci – non-glandular stomach (in 5 of 5 rats).
POLIOL MB 600 at 1000 mg/kg b. wt. /day
Three mortalities (2 male and 1 female rats) were observed.
Three male and four female rats were sacrificed under moribund condition.
Treatment related clinical signs viz. weakness, salivation, piloerection and polyuria were observed in all male and female rats.
Internal examination of found dead male rats revealed gaseous distension of stomach (in 2 of 2 rats) and gaseous distension of intestine (in 1 of 2 rats).
Internal examination of found dead female rat revealed gaseous distension of stomach.
Internal examination of moribundly sacrificed male rats revealed gaseous distension of stomac (in 1 of 3 rats), whitish foci – non-glandular stomach, (in 3 of 3 rats) and reddish foci – non-
glandular stomach (in 1 of 3 rats).
Internal examination of moribundly sacrificed female rats revealed gaseous distension of stomach (in 3 of 4 rats) and whitish foci – non-glandular stomach, (in 3 of 4 rats).
In male rats, statistically significant decrease in absolute weight of thymus, prostate, and LABC
and relative weight of prostate were observed. In female rats, statistically significant increasein absolute and relative weight of spleen was observed. These changes in organ weights
(absolute and relative) were considered as treatment related however adversity of effect couldnot be established due to limited end-points of this study.
Conclusion:
Based on the results of present study, under the condition and procedures followed, dose levels of 1000 and
500 mg/kg b. wt. produced severe toxicity viz. treatment related mortality, morbidity, and adverse clinical
signs whereas a dose level of 250 mg/kg b. wt. produced mild toxicity viz. decreased body weight change
(7.90% in males), food consumption and treatment related changes in absolute and relative organ weight.
Hence, following dose levels are suggested for reproduction/ developmental toxicity screening study (dose
range finding study):
Options Low dose Mid dose High dose
I 15 50 150
II 15 60 240
III 20 60 180
(mg/kg b. wt/day)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
